scholarly journals Glycyrrhetinic acid-functionalized mesoporous silica nanoparticles as hepatocellular carcinoma-targeted drug carrier

2017 ◽  
Vol Volume 12 ◽  
pp. 4361-4370 ◽  
Author(s):  
Yongjiu Lv ◽  
Jingjing Li ◽  
Huali Chen ◽  
Yan Bai ◽  
Liangke Zhang
Keyword(s):  
Hepatocellular Carcinoma ◽  
Mesoporous Silica ◽  
Silica Nanoparticles ◽  
Mesoporous Silica Nanoparticles ◽  
Drug Carrier ◽  
Glycyrrhetinic Acid ◽  
Functionalized Mesoporous Silica ◽  
Targeted Drug

Stimuli-responsive delivery vehicles based on mesoporous silica nanoparticles: recent advances and challenges

2017 ◽  
Vol 5 (7) ◽  
pp. 1339-1352 ◽  
Author(s):  
Jianhua Zhu ◽  
Yimin Niu ◽  
Yang Li ◽  
Yaxiang Gong ◽  
Huihui Shi ◽  
...  
Keyword(s):  
Mesoporous Silica ◽  
Silica Nanoparticles ◽  
Mesoporous Silica Nanoparticles ◽  
Drug Carrier ◽  
Stimuli Responsive ◽  
Drug Delivery Vehicles ◽  
The Past ◽  
Functionalized Mesoporous Silica ◽  
New Type ◽  
Delivery Vehicles

In the past decade, stimuli-responsive drug delivery vehicles based on surface-functionalized mesoporous silica nanoparticles have attracted intense interest as a new type of drug carrier.

scholarly journals Immune response to functionalized mesoporous silica nanoparticles for targeted drug delivery

Nanoscale ◽  
2016 ◽  
Vol 8 (2) ◽  
pp. 938-948 ◽  
Author(s):  
Simon Heidegger ◽  
Dorothée Gößl ◽  
Alexandra Schmidt ◽  
Stefan Niedermayer ◽  
Christian Argyo ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Immune Response ◽  
Mesoporous Silica ◽  
Silica Nanoparticles ◽  
Immune Cells ◽  
Targeted Drug Delivery ◽  
Mesoporous Silica Nanoparticles ◽  
Delivery Vehicle ◽  
Functionalized Mesoporous Silica ◽  
Targeted Drug

Mesoporous silica nanoparticles represent an efficient drug delivery vehicle to primary immune cells that is both non-toxic and non-inflammagenic.

scholarly journals ADAM9-Responsive Mesoporous Silica Nanoparticles for Targeted Drug Delivery in Pancreatic Cancer

Cancers ◽  
2021 ◽  
Vol 13 (13) ◽  
pp. 3321
Author(s):  
Etienne J. Slapak ◽  
Lily Kong ◽  
Mouad el Mandili ◽  
Rienk Nieuwland ◽  
Alexander Kros ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Mesoporous Silica ◽  
Silica Nanoparticles ◽  
Conditioned Medium ◽  
Drug Delivery System ◽  
Delivery System ◽  
Targeted Drug Delivery ◽  
Mesoporous Silica Nanoparticles ◽  
Pdac Cell ◽  
Targeted Drug

Pancreatic ductal adenocarcinoma (PDAC) has the worst survival rate of all cancers. This poor prognosis results from the lack of efficient systemic treatment regimens, demanding high-dose chemotherapy that causes severe side effects. To overcome dose-dependent toxicities, we explored the efficacy of targeted drug delivery using a protease-dependent drug-release system. To this end, we developed a PDAC-specific drug delivery system based on mesoporous silica nanoparticles (MSN) functionalized with an avidin–biotin gatekeeper system containing a protease linker that is specifically cleaved by tumor cells. Bioinformatic analysis identified ADAM9 as a PDAC-enriched protease, and PDAC cell-derived conditioned medium efficiently cleaved protease linkers containing ADAM9 substrates. Cleavage was PDAC specific as conditioned medium from leukocytes was unable to cleave the ADAM9 substrate. Protease linker-functionalized MSNs were efficiently capped with avidin, and cap removal was confirmed to occur in the presence of PDAC cell-derived ADAM9. Subsequent treatment of PDAC cells in vitro with paclitaxel-loaded MSNs indeed showed high cytotoxicity, whereas no cell death was observed in white blood cell-derived cell lines, confirming efficacy of the nanoparticle-mediated drug delivery system. Taken together, this research introduces a novel ADAM9-responsive, protease-dependent, drug delivery system for PDAC as a promising tool to reduce the cytotoxicity of systemic chemotherapy.

Sign in / Sign up

Export Citation Format

Share Document